NEUROSTIMULATION TREATMENT FOR OVERACTIVE BLADDER: AN EVALUATION OF COST EFFECTIVENESS DATA

被引：0
|
作者：
MacDiarmid, Scott
Martinson, Melissa
Black, Edward
机构：
来源：
JOURNAL OF UROLOGY | 2012年 / 187卷 / 04期
关键词：
D O I：
10.1016/j.juro.2012.02.1425
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
1180
引用
收藏
页码：E478 / E478
页数：1
相关论文
共 50 条
  • [21] A Cost-Effectiveness Analysis of Onabotulinumtoxin A as First-Line Treatment for Overactive Bladder
    不详
    [J]. OBSTETRICAL & GYNECOLOGICAL SURVEY, 2018, 73 (11) : 629 - 630
  • [22] A cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactive bladder
    Shepherd, Jonathan P.
    Carter-Brooks, Charelle M.
    Chermanksy, Christopher
    [J]. INTERNATIONAL UROGYNECOLOGY JOURNAL, 2018, 29 (08) : 1213 - 1219
  • [23] COST-EFFECTIVENESS OF TOLTERODINE AS TREATMENT FOR OVERACTIVE BLADDER (OAB) IN ADULT MEXICAN PATIENTS
    Arreola-Ornelas, H.
    Rosado-Buzzo, A.
    Garcia-Mollinedo, M.
    Camacho-Cordero, L.
    Mucino-Ortega, E.
    Mould-Quevedo, J. F.
    Galindo-Suarez, R. M.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A76 - A76
  • [24] Evaluation and Treatment of Overactive Bladder in Women
    Raju, Rubin
    Linder, Brian J.
    [J]. MAYO CLINIC PROCEEDINGS, 2020, 95 (02) : 370 - 377
  • [25] Sacral electrical neurostimulation in the refractory pediatric overactive bladder
    Casal-Beloy, I
    Garcia-Novoa, M. A.
    Casal Beloy, T.
    Garcia Gonzalez, M.
    Somoza Argibay, I
    [J]. ANALES DEL SISTEMA SANITARIO DE NAVARRA, 2020, 43 (03) : 417 - 421
  • [26] Commentary on: A cost-effectiveness analysis of onabotulinumtoxin A as first-line treatment for overactive bladder
    Abdelrahman, Abdelmageed
    [J]. INTERNATIONAL UROGYNECOLOGY JOURNAL, 2018, 29 (08) : 1221 - 1221
  • [27] Cost Effectiveness of Fesoterodine and Tolterodine for the Treatment of Overactive Bladder with Urge Urinary Incontinence in Spain and Finland
    Javier C. Angulo
    Antti Valpas
    Javier Rejas
    Kari Linden
    Marion Kvasz
    Sonya J. Snedecor
    [J]. Clinical Drug Investigation, 2014, 34 : 297 - 307
  • [28] COST-EFFECTIVENESS OF MIRABEGRON COMPARED WITH ANTIMUSCARINICS FOR THE TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER IN THE UNITED KINGDOM
    Maman, K.
    Neine, M.
    Briquet, B.
    Nazir, J.
    Odeyemi, I. A. O.
    Hakimi, Z.
    Garnham, A.
    Aballea, S.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A633 - A634
  • [29] Commentary on: A cost-effectiveness analysis of onabotulinumtoxin A as first-line treatment for overactive bladder
    Abdelmageed Abdelrahman
    [J]. International Urogynecology Journal, 2018, 29 : 1221 - 1221
  • [30] COST-EFFECTIVENESS ANALYSIS OF SACRAL NEUROMODULATION AND BOTULINE TOXIN A TREATMENT FOR PATIENTS WITH OVERACTIVE BLADDER
    Leong, R. K.
    Weil, E. H. J.
    Van Kerrebroeck, P. E. V.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 242 - 242
12345